Article
A novel neutralizing human monoclonal antibody broadly abrogates hepatitis C virus infection in vitro and in vivo.
Antiviral research - 1 Dec 2017
Desombere Isabelle, Mesalam Ahmed Atef, Urbanowicz Richard A, Van Houtte Freya, Verhoye Lieven, Keck Zhen-Yong, Farhoudi Ali, Vercauteren Koen, Weening Karin E, Baumert Thomas F, Patel Arvind H, Foung Steven K H, Ball Jonathan, Leroux-Roels Geert, Meuleman Philip
Abstract excerpt
Infections with hepatitis C virus (HCV) represent a worldwide health burden and a prophylactic vaccine is still not available. Liver transplantation (LT) is often the only option for patients with HCV-induced end-stage liver disease. However, immediately after transplantation, the liver graft becomes infected by circulating virus, resulting in accelerated progression of liver disease. Although the efficacy of HCV...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.